FR2870455A1 - Composition, useful in cosmetic procedure of whitening and/or bleaching of skin and/or hair of the body, comprises external aqueous phase, lipid lamellae phase and a compound (pantetheine sulfonic acid) - Google Patents

Abstract

Composition (A) comprises external aqueous phase (I), lipid lamellae phase (II) (comprising amphiphilic lipid (which forms dispersed vesicles) and encapsulating internal aqueous phase (III)) and a compound (pantetheine sulfonic acid (IV) or its salt). ACTIVITY : Dermatological. MECHANISM OF ACTION : None given.

Description

The present invention relates to a composition comprising vesicles

  formed of lamellar phases and containing at least one compound selected from pantethine sulfonic acid and a salt thereof, as well as its cosmetic applications.

  Pantethinesulfonic acid and its salts are active ingredients commonly used in cosmetics. They have in particular been described as agents promoting hair regrowth (JP-09 110 645), as agents for whitening the skin (JP-09 059 142), in particular by inhibiting the activity of tyrosinase (FR-2,532 175), and to increase cell turnover, particularly in anti-aging compositions further containing a hydroxy acid (JP-08 259 420). It has also been suggested to use them to inhibit skin irritation (JP-03 054 081). Finally, these compounds are known for their anti-radical properties helping to prevent or fight against the effects of ultraviolet radiation and / or pollution on the skin (EP-1 293 193).

  However, the Applicant has discovered that the incorporation of these active ingredients in compositions, in particular in cosmetic compositions, posed certain difficulties due to stability problems and to the very nature of the asset. More particularly, it has been observed that pantethinesulfonic acid or its salts exhibit accelerated degradation with temperature. This implies that to achieve the desired effect, it is necessary to use a large amount of the asset. However, because of the ionic nature of these compounds, their introduction into compositions in too large amounts leads to destabilization of these compositions, in particular when they are gelled, which can in particular lead to a drop in viscosity over time and thus alter their cosmetic properties.

  On the basis of this finding, the Applicant has demonstrated that it is possible to solve the problems mentioned above and to use a minimum amount of an active ingredient chosen from pantethine sulfonic acid and its salts to obtain the effectiveness desired by incorporating said active agents in the heart of vesicles having lipidic lamellar walls.

  The present invention therefore relates to a composition comprising, in an external aqueous phase, a dispersion of vesicles formed by lipidic lamellar phases comprising at least one amphiphilic lipid and encapsulating an internal aqueous phase, and at least one compound chosen from pantethine sulfonic acid. and a salt thereof contained in the internal aqueous phase.

  When the composition according to the invention contains a salt of pantethine sulfonic acid, the latter is preferably an alkali metal or alkaline earth metal salt.

  A compound that is particularly suitable for the implementation of the present invention is the calcium salt of pantethinesulphonic acid, which is in particular commercially available from the company SOGO PHARMACEUTICAL.

  The vesicles used for the implementation of the present invention are lipid lamellar vesicles with an aqueous core, that is to say, encapsulating an aqueous phase, which is the internal aqueous phase. These vesicles may be either niosomes of the type described in application EP 0 582 503, the teaching of which is incorporated herein by reference, or the like, or liposomes of conventional type.

  In the case of niosomes, the lamellar phases comprise at least one nonionic amphiphilic lipid, chosen from polyol alkyl or polyalkyl esters, optionally oxyethylenated, and polyol ethers, optionally oxyethylenated, having a melting point of at least 40. vs.

  Nonionic amphiphilic lipids that are suitable for use in the present invention include glycolipids of natural or synthetic origin (for example cerebrosides), or mixtures of polyol esters and at least one hydrocarbon-chain acid. saturated compound comprising at least 14 carbon atoms, as well as polyol ethers and at least one saturated hydrocarbon chain alcohol comprising at least 14 carbon atoms.

  By "ester mixture" is meant not only mixtures of pure esters of different chemical families, but also any product containing several chemically pure polyol esters of the same family in varying proportions, such as polyglycerol esters comprising a statistical number of glycerol units.

  The nonionic amphiphilic lipid may thus consist of a mixture of esters of at least one polyol selected from the group consisting of polyethylene glycol having 1 to 60 ethylene oxide units, sorbitan, sorbitan carrying 2 to 60 units ethylene oxide, glycerol carrying 2 to 30 ethylene oxide units, polyglycerols comprising 2 to 15 units of glycerol, sucroses, glucose containing 2 to 30 ethylene oxide units, and at least one fatty acid comprising a linear or branched C14-C20 hydrocarbon chain, saturated or unsaturated.

  As polyol ethers which may be used according to the invention, mention may be made of: linear or branched polyglycerol ethers of the formulas R - (OCH 2 - CH (OH) - CH 2) n - OH (I) and R - (O - CH 2 -CH (CH 2 OH) n -OH (II) wherein n is an integer between 1 and 6, preferably 2, and R is a radical chosen from: (a) a linear or branched, saturated or unsaturated aliphatic chain comprising from 14 to 30 carbon atoms, such as a tetradecyl, hexadecyl radical or the alkyl radical of oleic alcohol or isostearyl alcohol; (b) a hydrocarbon radical of lanolin alcohol; (c) a hydroxy-2-alkyl residue of a diol whose hydrocarbon chain comprises at least 14 carbon atoms; and polyoxyethylenated fatty alcohols, such as oleyl alcohol oxyethylenated to 10 moles (product "Brij 96" marketed by the company Uniqema).

  Moreover, in order to improve the stability of the niosomes as described above, the lamellar phases may also comprise an ionic amphiphilic lipid. The latter may be chosen from anionic lipids and cationic lipids.

  The anionic amphiphilic lipids suitable for the implementation of the invention may be: neutralized anionic lipids, preferably chosen from the alkaline salts of dicetyl phosphate and dimyristyl phosphate, in particular the sodium and potassium salts, the salts phosphatidic acid alkalis, in particular the sodium salt, the alkaline salts of cholesterol sulfate, in particular the sodium salt, the alkaline salts of cholesterol-phosphate, in particular the sodium salt, the lipoamino acid salts such as mono- and disodium acylglutamates, more particularly the disodium salt of N-stearoyl L-glutamic acid marketed under the name Acylglutamate HS21 by the company Ajinomoto, and amphoteric lipids, preferably phospholipids, in particular pure soybean phosphatidylethanolamine ; alkylsulphonic derivatives, in particular the compounds of formula: ## STR2 ## wherein R represents a C 12 -C 22 hydrocarbon radical, in particular the radicals C 16 H 33 and C 16 H 37, and M is a alkali metal, preferably sodium.

  The cationic amphiphilic lipids which may be used in the vesicles of the invention as ionic amphiphilic lipids may more particularly be selected from the group consisting of quaternary ammonium salts, fatty amines and their salts.

  Among the ammonium salts particularly suitable for one embodiment of the invention are those represented by the following formula (II): ## STR2 ## R3 R2 R4 in which the radicals R1 to R4, which may be identical or different, represent a linear or branched aliphatic radical containing from 1 to 30 carbon atoms, or an aromatic radical such as aryl or alkylaryl. The aliphatic radicals can comprise heteroatoms such as in particular oxygen, nitrogen, sulfur, halogens. The aliphatic radicals are, for example, chosen from alkyl, alkoxy, polyoxyalkylene (C 2 -C 6), alkylamide, (C 12 -C 22) alkylamido (C 2 -C 6) alkyl, (C 12 -C 22) alkyl acetate, hydroxyalkyl radicals comprising from about 1 to 30 carbon atoms; X is an anion selected from the group of halides, phosphates, acetates, lactates, (C 2 -C 6) alkyl sulfates, alkyl or alkylarylsulfonates. As quaternary ammonium salts of formula (II), it is preferred, on the one hand, tetraalkylammonium chlorides such as dialkyldimethylammonium chloride or alkyltrimethylammonium, in which the alkyl radical comprises about 12 to 22 carbon atoms , in particular behenyltrimethylammonium, distearyldimethylammonium, cetyltrimethylammonium, benzyl dimethylstearylammonium chlorides or else stearamidopropyldimethyl (myristyl acetate) ammonium chloride sold under the name CERAPHYL 70 by VAN DYK.

  quaternary ammonium salts of imidazolinium, for example represented by the following formula (III):

R

CH2-CH2-N (R8) -CO-R5

NN <R7

  in which R5 represents an alkenyl or alkyl radical containing from 8 to 30 carbon atoms, for example derived from tallow fatty acids; R6 represents a hydrogen atom, an alkyl radical containing from 1 to 4 carbon atoms or an alkenyl or alkyl radical containing from 8 to 30 carbon atoms; R7 represents an alkyl radical having 1 to 4 carbon atoms; R8 represents a hydrogen atom, an alkyl radical having 1 to 4 carbon atoms; X is an anion selected from the group of halides, phosphates, acetates, lactates, alkylsulfates, alkyl-or-alkylarylsulfonates. Preferably, R 5 and R 6 denote a mixture of alkenyl or alkyl radicals containing from 12 to 21 carbon atoms, for example fatty acid derivatives of tallow, R 7 denotes a methyl radical and R 8 denotes hydrogen. Such a product is for example sold under the name REWOQUAT W 75 by the company REWO.

  quaternary diammonium salts represented by the following formula (IV): embedded image in which R 6 denotes an aliphatic radical having about 16 to 30 carbon atoms; R7, R8, R9, R10, and R11, which are identical or different, are chosen from hydrogen or an alkyl radical containing from 1 to 4 carbon atoms; and X is an anion selected from the group of halides, acetates, phosphates, nitrates and methylsulfates. Such diammonium quaternary salts include in particular propane dichloride diammonium.

  In addition to the nonionic and ionic amphiphilic lipids, the lamellar phases of the niosome-type vesicles may also contain at least one additive chosen from sterols, fatty-chain alcohols and diols, fatty-chain amines and their quaternary ammonium derivatives.

  It is preferred to use cholesterol which, in addition to its cosmetic and / or dermopharmaceutical activity related to its ability to reconstitute lipids of the skin, improves the stability of the vesicles by avoiding the crystallization of the surfactants with which it is associated. By improving the impermeability of the lamellar phases of the vesicles, cholesterol also makes it possible to increase the retention capacity of the water-soluble active agents that may be contained in the aqueous phase encapsulated by the niosomes.

  The lamellar phases of the niosome-type vesicles may, for example, contain from 35 to 90% by weight of nonionic amphiphilic lipid, from 0 to 20% by weight of ionic amphiphilic lipid, from 5 to 50% by weight of cholesterol, relative to total weight of the constitutive lipids of the lamellar phase.

  As indicated above, the lipidic lamellar vesicles according to the invention may comprise not only nonionic type vesicles such as niosomes, but also conventional liposomes, comprising at least one ionic amphiphilic lipid such as a natural or synthetic phospholipid, in particular in particular lecithin, preferably hydrogenated, associated either with cholesterol and optionally with an ionic surfactant, or with an oxyethylenated phytosterol comprising from 2 to 50 ethylene oxide units.

  2X (IV) The methods of manufacturing the vesicles according to the invention are known to those skilled in the art, but the preferred methods are as follows: E Bangham method The vesicular lipids are solubilized in a mixture of organic solvents. This mixture is then placed in a flask and the solvents are evaporated in a rotary evaporator under reduced pressure. A lipid film is formed then. After complete evaporation of the solvents, the film is hydrated with an aqueous solution, with vigorous stirring. The temperature is adapted to the melting temperature of the lipids. A suspension of liposomes is then obtained. It is then possible to homogenize it using ultrasound.

  Direct lipid hydration method Lipids may have been preassociated or not (by fusion or by solvent). The lipid mixture is then introduced with vigorous stirring (stator rotor for example) in an aqueous solution at a suitable temperature. After a few minutes (usually 5 to 90 minutes), a suspension of liposomes is obtained. It is thus in the presence of an aqueous dispersion.

  In a preferred embodiment of the invention, the lipids constituting the vesicles represent an amount ranging from 0.05% to 5% by weight relative to the total weight of the composition, and preferably from 0.1% to 2%. by weight relative to the total weight of the composition.

  The pantethinesulphonic acid or its salts are preferably present in the vesicles in an amount ranging from 1% to 20%, and more preferably from 5% to 15% by weight relative to the total weight of the lipids constituting the vesicles.

  Panthein sulfonic acid or its salts thus generally represents from 0.0001 to 10%, and preferably from 0.001% to 5% of the total weight of the composition.

  The encapsulated aqueous phase may contain, in addition to water, various additives such as surfactants, preservatives or sequestering agents. The vesicles of the compositions according to the invention may contain, in addition, one or more other compound (s). ) active (s) having a cosmetic activity and / or dermopharmaceutical, which, according to their solubility characteristics, may have different locations.

  If the active ingredients are water-soluble, they are introduced into the encapsulated hydrophilic phase of the vesicles.

  If the active ingredients are fat-soluble, they are introduced into the lipid phase constituting the membrane.

  If the active agents are amphiphilic, they are distributed between the lipid phase and the encapsulated hydrophilic phase with a partition coefficient, which varies according to the nature of the amphiphilic active agent and the respective compositions of the lipid phase and the encapsulated aqueous phase.

  In the composition according to the invention, the aqueous core vesicles previously described (niosomes or liposomes) are dispersed in an aqueous dispersion phase, or external aqueous phase, comprising a physiologically acceptable medium, that is to say compatible with the skin or its integuments, and possibly with the mucous membranes and / or semimuqueuses.

  The aqueous dispersion phase can be gelled. Gelling agents that can be used according to the invention are, for example, carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides such as partially neutralized and highly crosslinked polyacrylamidomethylpropane sulfonic acid, polysaccharides, natural gums and clays.

  Alternatively, the aqueous dispersion phase may comprise an oily phase dispersed in said aqueous phase (oil-in-water emulsion), and / or be dispersed itself in an oily phase (water-in-oil emulsion).

  Suitable oils according to the invention include animal or vegetable oils, natural or synthetic essential oils, hydrocarbons such as isohexadecane and paraffin oil, halogenated carbides and silicone oils.

  As animal or vegetable oils that can be used according to the invention, mention may be made especially of animal or vegetable oils formed by esters of fatty acids and of polyols, in particular liquid triglycerides, for example sunflower, corn or soybean oils. , squash, grape seed, jojoba, sesame, hazelnut, fish oils, tricaprocaprylate glycerol, or vegetable or animal oils of the formula R1000R2i wherein R1 represents the remainder of a higher fatty acid with 7 to 19 carbon atoms and R2 represents a branched hydrocarbon chain containing from 3 to 20 carbon atoms, for example purcellin oil.

  As essential oils that may be used according to the invention, mention may be made of natural or synthetic essential oils such as, for example, eucalyptus, lavandin, lavender, vetiver, litsea cubeba, lemon, sandalwood, rosemary, chamomile, savory nutmeg, hyssop cinnamon, caraway, orange, geraniol, cade and bergamot.

  As halogenated carbides that may be used according to the invention, mention may be made of fluorocarbons such as fluoroamines, for example perfluorotributylamine, fluorinated hydrocarbons, for example perfluorodecahydronaphthalene, fluoroesters and fluoroethers.

  In the case where the vesicles according to the invention are dispersed in the aqueous phase of an oil-in-water emulsion, said emulsion may comprise surfactants other than those constituting the vesicles, provided that these surfactants do not solubilize the vesicles. forming micelles.

  According to another possibility, however, the composition according to the invention, when it is in the form of oil-in-water emulsion, may not contain any other surfactant than those forming the lipidic lamellar vesicles. The vesicles according to the invention can indeed be able to stabilize a dispersion of oil droplets in the aqueous dispersion phase, without the need to add a surfactant to said aqueous phase.

  Of course, the composition according to the invention may alternatively be in the form of a multiple water-in-oil-in-water or oil-in-water-in-oil emulsion whose aqueous and oily phases are such that defined above.

  In a known manner, the composition according to the invention may also contain adjuvants which are customary in the cosmetic field, such as preservatives, antioxidants, solvents, perfumes, odor absorbers, neutralizers, sunscreens, polymers , emulsifiers and coemulsifiers, and dyestuffs.

  As active agents, it is possible to use in particular desquamating agents, moisturizing agents, depigmenting or pro-pigmenting agents, anti-glycation agents, NO-synthase inhibitors, 5α-reductase inhibitors, lysyl inhibitors and / or prolyl hydroxylase, the agents stimulating the synthesis of dermal or epidermal macromolecules and / or preventing their degradation, the agents stimulating the proliferation of fibroblasts or keratinocytes and / or the differentiation of keratinocytes, the muscle relaxant or dermo-decontracting agents, the anti-inflammatory agents. -microbial agents, tensors, anti-pollution or anti-radical agents, anti-inflammatory agents, lipolytic active agents or having a favorable activity, direct or indirect, on the reduction of adipose tissue, agents acting on microcirculation, and agents acting on the energetic metabolism of cells.

  In an advantageous aspect of the invention, the composition used can thus contain at least one desquamating agent.

  By "desquamating agent" is meant any compound capable of acting: either directly on the desquamation by promoting the exfoliation, such as the 13-hydroxy acids, in particular salicylic acid and its derivatives (whose acid n 5-salicylic octanoyl); ahydroxyacids, such as glycolic, citric, lactic, tartaric, malic or mandelic acids; urea; gentisic acid; oligofucoses; cinnamic acid; the extract of Sophora japonica; resveratrol; or on the enzymes involved in the desquamation or degradation of corneodesmosomes, glycosidases, stratum corneum chymotryptic enzyme (SCCE) or even other proteases (trypsin, chymotrypsin-like). Mention may be made of chelating agents for mineral salts: EDTA; N-acyl-N, N ', N', ethylene diaminetriacetic acid; aminosulfonic compounds and in particular (N-2-hydroxyethylpiperazine-N-2-ethane) sulfonic acid (HEPES); 2-oxothiazolidine-4-carboxylic acid derivatives (procysteine); glycine-type alpha amino acid derivatives (as described in EP-0 852 949, as well as the sodium methyl glycine diacetate marketed by BASF under the trade name TRILON M); honey; sugar derivatives such as O-octanoyl-6-D-maltose and N-acetyl glucosamine.

  In an advantageous aspect of the invention, the composition used may additionally or alternatively contain at least one depigmenting or antipigmenting active agent.

  The depigmenting or antipigmenting agents that may be incorporated in the composition according to the present invention comprise, for example, the following compounds: kojic acid; ellagic acid; Arbutin and its derivatives such as those described in EP-895,779 and EP-524,109; hydroquinone; aminophenol derivatives such as those described in applications WO 99/10318 and WO 99/32077, and in particular the Ncholesteryloxycarbonyl-para-aminophenol and N-ethyloxycarbonyl-paraaminophenol; iminophenol derivatives, in particular those described in application WO 99/22707; L-2-oxothiazolidine-4-carboxylic acid, as well as its salts and esters; ascorbic acid and its derivatives, in particular ascorbyl glucoside and magnesium ascorbyl phosphate, 4-butyl-resorcinol or lucinol, thiourea and its derivatives; and plant extracts, in particular of bearberry, licorice, mulberry and skullcap, without this list being limiting.

  According to a preferred embodiment, the compositions in accordance with the invention may further comprise at least one organic photoprotective agent and / or at least one active inorganic photoprotective agent in the UVA and / or the UVB (absorbers), which are water-soluble or liposoluble or insoluble in commonly used cosmetic solvents.

  The organic photoprotective agents are in particular chosen from anthranilates; cinnamic derivatives; dibenzoylmethane derivatives; salicylic derivatives, camphor derivatives; triazine derivatives such as those described in patent applications US 4367390, EP863145, EP517104, EP570838, EP796851, EP775698, EP878469, EP933376, EP507691, EP507692, EP790243, EP944624; benzophenone derivatives; derivatives of R, (i-diphenylacrylate, benzotriazole derivatives, benzalmalonate derivatives, benzimidazole derivatives, imidazolines, bis-benzoazolyl derivatives as described in patents EP669323 and US 2,463,264; paminobenzoic acid (PABA), methylene bis- (hydroxyphenylbenzotriazole) derivatives as described in US5,237,071, US5,166,355, GB2303549, DE 197 26 184 and EP893119, filter and silicone filter polymers such as those described in particular. in the application WO-93/04665, dimers derived from α-alkylstyrene such as those described in patent application DE19855649, 4,4-diarylbutadienes as described in applications EP0967200, DE19746654, DE19755649, EP-A- 1008586, EP1133980 and EP133981 and mixtures thereof.

  The more particularly preferred organic photoprotective agents are chosen from ethylhexyl salicylate, ethylhexyl methoxycinnamate, octocrylene, phenylbenzimidazole sulphonic acid, benzophenone-3, benzophenone-4, benzophenone-5, 4-methylbenzylidene camphor, terephthalylidene dicamphor sulphonic acid, disodium phenyl dibenzimidazole tetra-sulphonate, 2,4,6-tris- (4'-amino benzalmalonate diisobutyl) -triazine, anisotriazine, ethylhexyl triazone, diethylhexyl butamido triazone, methylene bis-benzotriazolyl tetramethylbutylphenol, drometrizole trisiloxane, and mixtures thereof.

  The inorganic photoprotective agents are chosen from pigments or even nanopigments (average size of the primary particles: generally between 5 nm and 100 nm, preferably between 10 nm and 50 nm) of coated or uncoated metal oxides such as, for example, nanopigments titanium oxide (amorphous or crystallized in rutile and / or anatase form), iron, zinc, zirconium or cerium which are all UV photoprotective agents well known per se. Conventional coating agents are, moreover, alumina and / or aluminum stearate. Such nanopigments of metal oxides, coated or uncoated, are in particular described in patent applications EP518772 and EP518773.

  The photoprotective agents are generally present in the compositions according to the invention in proportions ranging from 0.1 to 20% by weight relative to the total weight of the composition, and preferably ranging from 0.2 to 15% by weight relative to to the total weight of the composition.

  The composition according to the invention can be used to prevent and / or fight against the signs of skin aging and / or the effects of pollution.

  The present invention more particularly relates to a cosmetic process for bleaching and / or lightening human skin and / or hair and / or hair comprising the application to the skin and / or the hair and / or the hair, of a cosmetic composition as defined above.

  The examples which follow illustrate the invention without limiting its scope. The compounds are, as the case may be, listed in chemical names or CTFA names (International Cosmetic Ingredient Dictionary and Handbook).

EXAMPLES

  Example 1: Preparation of calcium salt-based niosomes of pantethine sulfonic acid

  The following mixture was prepared: Sorbitan Palmitate Disodium Acrylglutamate 6.75% 1.5% Cholesterol 6.75% Calcium Salt of Panthein Sulfonic Acid 1% EDTA 1% Preservatives 1% Water qs 100% Procedure: After have carried the water, calcium pantone sulfonate and EDTA at 80 C with stirring, add the anionic surfactant (disodium acylglutamate) nonionic surfactant (sorbitan palmitate) and cholesterol. It is left for 1 hour at 80 ° C.

  EXAMPLE 2 Oil-in-Water Fluid The following composition was prepared: Phase A Mixture of Arachidyl Polyglucoside and Arachidic and Behenic Alcohols (15/85) Stearic Acid Cyclohexasiloxane Hydrogenated Isoparaffin Fragrance Phase B: Water Glycerin Carbomer Preservatives Phase C: Triethanolamine Preparation of niosomes of Example 1 Procedure: The constituents of phase A are heated, then phase B is added and the two phases are mixed and emulsified at 70 ° C. The temperature is then lowered to C. Then the mixture is neutralized with triethanolamine and the preparation of niosomes is added. This fluid can be used in bi-daily applications to fight

  against the effects of free radicals and pollution. 25 1%

  0.5% 4% 3% 0.1% 73% 7% 0.3% 0.6% 0.5% 11% Example 3: Day Cream SPF 15 Phase A: Stearic Acid 1.5% Glyceryl Stearate / PEG-100 Stearate 2% Ethylhexyl Methoxycinnamate 6% Dimethicone 4% Cyclopentasiloxane 7% Apricot Oil 2% Shea Butter 1% Perfume 0.3% Phase B: Water 50.25% Glycerin 4% Chlophenesin 0, 5% Titanium oxide 2% Polyacrylamido methyl propane sulfonic acid 1.3% Phase C: Silica microspheres 1% Phase D: Preparation of niosomes according to Example 1 15% Water 1.5% Diazolidinyl urea 0.15% Glucoside 0.5% ascorbyl Procedure: Phase A is heated to 80 ° C. and the clarity of the solution is checked. Phase B is then heated to 75 ° C. and added to phase A. The two phases are mixed and emulsified. The emulsion is then allowed to cool and the C and D phases are added. This cream can be used to whiten the skin of the face and hands.

  EXAMPLE 4 Night Fluid Phase A: Polysorbate 60 2% Cetyl alcohol 1% Hydrogenated polyisobutene 3% Cyclohexadimethylsiloxane 7% Perfume 0.2% Phase B: Water 58.4% Glycerine 5% 10 15 20 Propylene glycol 2% Preservative 0.3% Acrylic acid / methacrylate copolymer 0.5% stearyl (Pemulen TRI) Phase C: 0.1% triethanolamine Preservatives 0.2% Phase D: Tocopherol 0.3% Phase E: Preparation of niosomes according to Example 1 20% Mode Procedure: The constituents of phase A and phase B are heated separately. The two phases are mixed and emulsified at 70 ° C. The temperature is then lowered to 30 ° C. Then neutralized with TEA and the phases D and E are added. This cream can be applied to the face and hands to to lighten the spots of senescence.

  Example 5: Demonstration of the stability of the calcium salt of pantethine sulfonic acid: The stability of calcium salt of D-pantethine S-sulfonic acid was evaluated in the composition of Example 2 and in a composition identical to that of Example 2, except that pantethine sulfonic acid was in free form and not included in vesicles (comparative example).

  Protocol: Pantethine sulphonate calcium is determined by high performance liquid chromatography on a MERCK Lichrospher 100 NH2 column (5 μm) with a length of 250 mm and a diameter of 4.6 mm. Acetonitrile is used as the Muant in phosphate buffer at pH 2.1. The flow rate is set to 1 ml / min. The quantity injected is 10 μl. The extraction takes place at 210 nm. The retention time is about 8.5 minutes.

  The compound used as a standard is in the form of 70% raw material in water, supplied by the company SOGO PHARMACEUTICAL Results: The results are grouped in the following table: Composition Theoretical rate After 2 months at 45 ° C. Example 2 , 11 0, 104

Example 0.10 0.090

  These results show that in the compositions according to the invention, the calcium salt of pantethinesulphonic acid does not degrade, whereas in the composition used as a comparative example the degradation observed is of the order of 18. %.

Claims (20)

  A composition comprising, in an external aqueous phase, a dispersion of vesicles formed by lipidic lamellar phases comprising at least one amphiphilic lipid and encapsulating an internal aqueous phase, and at least one compound chosen from pantethine sulfonic acid and one of its salts, contained in the internal aqueous phase.   2. Composition according to claim 1, characterized in that the pantethinesulphonic acid salt is an alkali metal or alkaline earth metal salt.   3. The composition as claimed in claim 2, characterized in that the pantethine sulphonic acid salt is the calcium salt of pantethine sulphonic acid.   4. Composition according to one of claims 1 to 3 characterized in that the lamellar phases comprise at least one nonionic amphiphilic lipid selected from mixtures of polyol alkyl or polyalkyl esters, optionally oxyalkylenated, and alkyl or polyalkyl ethers of polyol, optionally oxyalkylenated, having a melting point of at least 40 C.   5. Composition according to claim 4, characterized in that said nonionic amphiphilic lipid is a mixture of polyol esters and at least one saturated hydrocarbon chain acid comprising at least 14 carbon atoms.   6. Composition according to claim 4, characterized in that said non-ionic amphiphilic lipid is a polyol ether and at least one saturated hydrocarbon chain alcohol comprising at least 14 carbon atoms.   7. Composition according to one of claims 4 to 6, characterized in that said nonionic amphiphilic lipid is constituted by a mixture of esters of at least one polyol selected from the group consisting of polyethylene glycol having from 1 to 60 units ethylene oxide, sorbitan, sorbitan carrying 2 to 60 ethylene oxide units, glycerol carrying 2 to 30 ethylene oxide units, polyglycerols comprising 2 to 15 glycerol units, sucroses, glucoses carrying 2 to 30 units of ethylene oxide, and of at least one fatty acid comprising a saturated or unsaturated, linear or branched C14-C20 hydrocarbon chain.   8. Composition according to one of claims 4 to 7, characterized in that the lamellar phases further comprise an ionic amphiphilic lipid.   9. Composition according to claim 8, characterized in that the ionic amphiphilic lipid is selected from the group formed by the alkali metal salts of dicetyl and dimyristylphosphate; alkaline salts of cholesterol sulfate; alkaline salts of cholesterol phosphate; mono- and disodium acylglutamates; the sodium salt of phosphatidic acid; phospholipids; and the alkylsulphonic derivatives, the ammonium salts represented by the following formula (II): ## STR1 ## in which the radicals R 1 to R 4, which may be identical or different, represent a linear or branched aliphatic radical; , having 1 to 30 carbon atoms, or an aromatic radical such as aryl or alkylaryl; X is an anion chosen from the group of halides, phosphates, acetates, lactates, (C 2 -C 6) alkyl sulphates, alkyl-or alkylarylsulphonates, quaternary ammonium salts of imidazolinium, for example represented by the following formula (III) : + R   In which R5 represents an alkenyl or alkyl radical containing from 8 to 30 carbon atoms, R6 represents a hydrogen atom, an alkyl radical containing from 1 to 4 carbon atoms, carbon or an alkenyl or alkyl radical having from 8 to 30 carbon atoms; R7 represents an alkyl radical having 1 to 4 carbon atoms; R8 represents a hydrogen atom, an alkyl radical having 1 to 4 carbon atoms; X is an anion selected from the group of halides, phosphates, acetates, lactates, alkylsulfates, alkylalkylarylsulfonates, and the quaternary diammonium salts represented by the following formula (IV): R10 R12 R9 N (CH2) 3 N R14 R11 R13 wherein R6 is an aliphatic radical having about 16 to 30 carbon atoms; R7, R8, R9, R10, and R11, which are identical or different, are chosen from hydrogen or an alkyl radical containing from 1 to 4 carbon atoms; and X is an anion selected from the group of halides, acetates, phosphates, nitrates and methylsulfates.   10. Composition according to any one of claims 4 to 9, characterized in that said lamellar phases contain at least one additive selected from sterols, fatty-chain alcohols and diols, fatty-chain amines and quaternary ammonium derivatives thereof.   11. Composition according to claim 10, characterized in that said additive is cholesterol.   12. Composition according to claim 11, characterized in that said lamellar phases comprise from 35 to 90% by weight of nonionic amphiphilic lipid, from 0 to 20% by weight of ionic amphiphilic lipid, and from 5 to 50% by weight of cholesterol, relative to the total weight of lipids constituting the lamellar phase.   13. Composition according to any one of claims 1 to 12, characterized in that the constitutive lipids of the vesicles represent from 0.05 to 5%, and preferably from 0.1 to 2%, of the total weight of the composition.   14. Composition according to any one of claims 1 to 13, characterized in that the pantethinesulphonic acid or its salts represents from 0.0001 to 10%, and preferably from 0.001% to 5% of the total weight of the composition .   15. Composition according to one of claims 1 to 14, characterized in that the pantethine sulfonic acid or its salts are present in the vesicles in an amount ranging from 2X (IV) of 1 to 20%, and more preferably from 5 to 15% by weight relative to the total weight of the lipids constituting the vesicles.   16. Composition according to any one of claims 1 to 15, characterized in that it further comprises an oily phase dispersed in the external aqueous phase and / or in which said external aqueous phase is dispersed.   17. Composition according to any one of the preceding claims, characterized in that it further comprises at least one other water-soluble, amphiphilic or fat-soluble active.   18. Composition according to one of claims 1 to 17, characterized in that it further comprises at least one desquamating agent, and / or at least one other depigmenting or antipigmenting active.   19. Composition according to any one of claims 1 to 18, characterized in that it further comprises at least one organic photoprotective agent and / or at least one active inorganic photoprotective agent in the UVA and / or UVB.   20. A cosmetic process for bleaching and / or lightening human skin and / or hair and / or hair comprising applying to the skin and / or the hair and / or the hair, a cosmetic composition according to one of claims 1 to 19.